Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisSARS-CoV-2 변이체에 대한 보호 예측 인자로서의 중화 항체 역가 및 부스팅의 영향: 메타 분석Meta-Analysis Published on 2022-01-012022-09-11 Journal: The Lancet. Microbe [Category] MERS, SARS, 변종, 진단, [키워드] Alpha analysed Analysis Antibody titre Beta booster vaccination correlated decrease decreases Effect Efficacy elicited Future In-vitro infected individual Infection infection with SARS-CoV-2 Medical Research Council medium Meta-analysis neutralisation neutralisation titre Neutralising activity not significantly different outcome predict predicted Predictive predictor reduced remained robust SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants serum Severe infection shown statistical model suggested symptomatic infection titre vaccination vaccination schedule Vaccine vaccine efficacy vaccine response vaccine responses Vaccines variant variants variants of concern virus virus infection waning immunity [DOI] 10.1016/S2666-5247(21)00267-6 PMC 바로가기 [Article Type] Meta-Analysis
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형Research Article Published on 2021-12-022022-08-13 Journal: PLoS Pathogens [Category] Biochemistry, SARS, 변종, 진단, [키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China [DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular responseSARS-CoV-2 mRNA 백신 BNT162b2는 일관된 교차 변형 체액 및 세포 반응을 유발합니다Observational Study Published on 2021-12-012022-09-10 Journal: Emerging Microbes & Infections [Category] SARS, 변종, 임상, 진단, 치료기술, [키워드] administration all subject Alpha antibody Antibody Response Antibody titre B.1 B.1.1.7 B.1.351 B.1.525 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine cellular response chemiluminescence immunoassay CLIA CLIA assay CLIA assays Cohort correlation Definition Delta dose Efficacy elicited Eta evaluated Gamma HCW HCWs Health care Health care worker humoral Humoral response immune evasion immune response immunoassays in vitro mRNA vaccine Neutralization assay Neutralizing activity NTA observé P.1 pandemic Protective protective neutralizing antibody provided quantity reliability robust SARS-CoV-2 SARS-CoV-2 bnt162b2 mRNA vaccine SARS-CoV-2 pandemic SARS-CoV-2 variants SARS-CoV-2 variants of concern strain Strains T-cell mediated respone T-cell Response tested the SARS-CoV-2 Trigger vaccinal vaccination variants of concern VoC [DOI] 10.1080/22221751.2021.2004866 PMC 바로가기 [Article Type] Observational Study
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trialResearch article Published on 2021-12-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 유전자 메커니즘, 임상, [키워드] adverse event Anti-RBD antibody Antibody titre Asymptomatic baseline booster cellular response clinical clinical trial convalescent COVID-19 Cuba dimeric elicited ELISA ENhance Environment evaluated finding funding greater Humoral response IFN-γ IgG increase in individual inhibitory Intramuscular injection Local median Mild minor natural immunity neutralization Open-label Partial Participants PCR-positive Primary outcome producing Public reactogenicity Receptor binding domain registry Reinfection reported safety profile SARS-CoV-2 Science secondary outcome Serious Adverse Event single dose subclinical infection T cell technology TNF-α vaccination Vaccine vaccine immunogenicity Virus neutralization titre [DOI] 10.1016/j.lana.2021.100079 [Article Type] Research article
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial건강한 소아 및 청소년을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 이중 맹검, 무작위, 대조, 1/2상 임상 시험Clinical Trial Published on 2021-12-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI Adverse reaction age All participants aluminum Antibody Response Antibody titre assigned Beijing block Block randomisation center children China Chinese clinical trial Control CoronaVac COVID-19 pandemic COVID-19 vaccine detectable development dose dose-escalation double-blind Endpoint enrolled geometric mean titre groups healthy children Humoral response hydroxide inactivated individual Infection injection injection site Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate MOST neutralising antibody occurred Pain participant Participants per-protocol population phase 1 trial Pneumonia prevention primary immunogenicity Program randomised Randomly receive Registered reported Safe Safety safety population safety profile SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Event Seroconversion seroconversion rate severity significant difference Support technology three group Tolerability vaccination Vaccine were excluded [DOI] 10.1016/S1473-3099(21)00319-4 PMC 바로가기 [Article Type] Clinical Trial
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis암환자의 코로나19 백신 반응 평가: 중간분석Review Published on 2021-12-012022-09-12 Journal: European journal of cancer (Oxford, England : 1990 [Category] MERS, SARS, 진단, [키워드] analysed Analysis anti-SARS-CoV-2 antibody Antibody titre Cancer cohorts collected COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines examined haematological malignancies healthy controls heterogeneous high-risk patient Immunity Immunoglobulin increase in Infection interim analysis Local malignancy Neoplasms Patient patient questionnaire Patients with cancer patients with haematological peer-reviewed Population Preliminary data prophylactic measure receive receiving reduced response risk of COVID-19 S1/S2 Safe SARS-CoV-2 SARS-COV-2 infection second dose Seroconversion serological serological response severe complication Side-effect significantly lower single dose solid cancer solid malignancies Spike protein Support systemic effects the SARS-CoV-2 These data Tumours vaccination [DOI] 10.1016/j.ejca.2021.10.013 PMC 바로가기 [Article Type] Review
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial5 개의 면역 저하 환자 및 전향 적 개방형 임상 시험에서 건강한 대조군에서 SARS-COV-2에 대한 mRNA BNT162B2 백신의 안전성 및 효능Research paper Published on 2021-11-302022-08-13 Journal: EBioMedicine [Category] MERS, SARS, 임상, [키워드] Adverse adverse events Adverse reaction Allogeneic allogeneic hematopoietic stem cell transplantation Antibody titre antibody titres BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination CAR T, Chimeric antigen receptor T CAR-T Cell Cell therapy certain immunocompromised patient groups chronic lymphocytic leukemia clinical trial clinical trials CLL CLL, Chronic lymphocytic leukemia Control controls Council COVID-19, Coronavirus disease 2019 disorder Efficacy event excluded finding FIVE five group foundation funding generally mild group healthy control healthy controls Hematopoietic stem cell highlight HIV HIV, Human immunodeficiency virus HSCT, Allogeneic hematopoietic stem cell transplantation Human immunodeficiency virus human stem-cell transplantation Ibrutinib Immunity Immunocompromised Immunocompromised patient immunocompromised patient group Immunocompromised patients immunodeficiency disorder immunodeficiency disorders IMPROVE Infection ITT, Intention to treat Knut leukemia Lymphocytic leukemia mPP, Modified per protocol mRNA BNT162b2 vaccine mRNA vaccination mycophenolate mycophenolate mofetil occurred of BNT162b2 Open-label organ transplantation organization organizations Patient patient group patient groups PID, Primary immunodeficiency disorders PP, Per protocol primary endpoint Primary Immunodeficiency Prospective clinical trial Rate Region Safe Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 second dose secondary endpoint Secondary endpoints selected serious adverse reaction Seroconversion seroconversion rate seroconverted solid organ solid organ transplantation SOT SOT, Solid organ transplantation stem cell subgroups subject Swedish T cell therapy Treatment vaccination against COVID-19 vaccine dose virus infection [DOI] 10.1016/j.ebiom.2021.103705 PMC 바로가기 [Article Type] Research paper
Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches정맥주사용 면역글로불린 제품 배치에서 항-SARS-CoV-2 면역글로불린 G의 농도 모델링Research Article Published on 2021-11-292022-09-12 Journal: PLoS ONE [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibody antibody half-life antibody levels Antibody titre anticipated binding Concentration convalescent convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 Diseases Donor early phase elevated expected group half-life IgG Immunoglobulin implication incidence indicated Intravenous immunoglobulin IVIG mathematical mathematical model measurement parameter Patient Phadia physician plasma plasma concentration predict produced reactivity Result retained SARS-CoV-2 SARS-CoV-2 vaccination status Study design the mean Vaccination Status were used [DOI] 10.1371/journal.pone.0259731 PMC 바로가기 [Article Type] Research Article
T cell-oriented strategies for controlling the COVID-19 pandemic코로나19 팬데믹을 통제하기 위한 T 세포 중심 전략Article Published on 2021-11-012022-09-11 Journal: Nature reviews. Immunology [Category] SARS, 변종, 임상, [키워드] antibody Antibody titre antibody titres conservation COVID-19 COVID-19 pandemic decay Epitopes Host Neutralizing antibodies neutralizing antibody pandemic protective role SARS-CoV-2 variant SARS-CoV-2 variants T cell T cell epitope T cell epitopes T cells thought vaccination variants of SARS-CoV-2 [DOI] 10.1038/s41577-021-00625-9 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric populationSARS-CoV-2 항체는 소아 인구에서 COVID-19 감염 후 4개월 만에 감소하기 시작했습니다Article Published on 2021-11-012022-09-12 Journal: Acta paediatrica (Oslo, Norway : 1992) [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome age antibody antibody levels Antibody testing Antibody titre Asymptomatic asymptomatic infection blood test center children cohort study coronavirus COVID-19 infection cross-sectional eligible evaluated had no Immunity Infection infection rates initial interquartile range intravenous access Jerusalem male not affect Older Patient patients Population Prevalence required SARS-CoV-2 SARS-CoV-2 antibody School School closures seropositive Seropositivity tested [DOI] 10.1111/apa.16031 PMC 바로가기 [Article Type] Article